In a 2001 study published in Endocrinology , Heffernan and colleagues reported that chronic AOD-9604 administration reduced body weight gain, decreased adipose tissue mass, and increased fat oxidation in obese mice without altering IGF-1 levels or glucose metabolism effects that were abolished in beta3 adrenergic receptor (3-AR) knockout mice, implicating 3-AR signaling as the mechanism of action [1]
What Makes BPC-157 So Talked About
Enhances post-meal fullness
The Joe Rogan effect in full swing Definitely seeing this become more common
Regulatory and Safety Context Since discontinuation, AOD-9604 has remained unapproved by major regulators such as the US FDA , EMA , and TGA
Upon oral ingestion, BPC-157 directly contacts the gastric and intestinal lining, promoting mucosal integrity, accelerating ulcer healing, and protecting against various digestive insults including NSAIDs and stress